{
    "2020-01-17": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Yacktman Focused Fund's Top 5 Sells in the 4th Quarter",
                "features": {
                    "keywords": [
                        "Yacktman",
                        "Focused",
                        "Fund",
                        "Top",
                        "Sells",
                        "4th",
                        "Quarter"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Judge Cuts $8 Billion J&J Jury Award to $6 Million",
                "features": {
                    "keywords": [
                        "Judge",
                        "Cuts",
                        "$8",
                        "Billion",
                        "J&J",
                        "Jury",
                        "Award",
                        "$6",
                        "Million"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Q4 Earnings Season Showing Revenue Momentum",
                "features": {
                    "keywords": [
                        "Q4",
                        "Earnings",
                        "Season",
                        "Revenue",
                        "Momentum"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Judge slashes $8 bln Risperdal award against Johnson & Johnson to $6.8 mln",
                "features": {
                    "keywords": [
                        "Judge",
                        "slashes",
                        "$8",
                        "bln",
                        "Risperdal",
                        "award",
                        "against",
                        "Johnson",
                        "&",
                        "Johnson",
                        "$6.8",
                        "mln"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "The Zacks Analyst Blog Highlights: AAPL, JNJ, PG and AXP",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Highlights",
                        "AAPL",
                        "JNJ",
                        "PG",
                        "AXP"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "healthcare",
                        "consumer goods",
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "The Zacks Analyst Blog Highlights: JPM, JNJ, CVX and PG",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Highlights",
                        "JPM",
                        "JNJ",
                        "CVX",
                        "PG"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "healthcare",
                        "energy",
                        "consumer goods"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Is Johnson & Johnson (JNJ) A Good Pick for Value Investors?",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "(JNJ)",
                        "Good",
                        "Pick",
                        "Value",
                        "Investors"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?",
                "features": {
                    "keywords": [
                        "J&J",
                        "(JNJ)",
                        "Roll",
                        "Out",
                        "Pharma",
                        "Q4",
                        "Earnings",
                        "Beat"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "Roundup",
                        "LLY",
                        "Dermira",
                        "Buyout",
                        "Offer",
                        "Pipeline",
                        "Regulatory",
                        "Updates"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}